Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth
of colorectal cancer by blocking blood flow to the tumor. Celecoxib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Giving cetuximab together
with celecoxib may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving cetuximab together with celecoxib
works in treating patients with metastatic colorectal cancer or colorectal cancer that cannot
be removed by surgery.